![Page 1: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/1.jpg)
NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR
ON INTEGRIN v3 TO PROMOTE APOPTOSIS,
DISRUPT CELL DEFENSE PATHWAYS AND BLOCK
ANGIOGENESIS
Paul J. Davis, MDShaker A. Mousa, PhD
Albany Medical College; Pharmaceutical Research Institute, Albany College of
Pharmacy and Health Sciences, Albany, NY, USA
![Page 2: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/2.jpg)
B Alberts text
X
![Page 3: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/3.jpg)
The thyroid hormone receptor on the extracellular domain of v3 binds L-thyroxine (T4), 3,5,3’-triiodo-L-thyronine (T3) and tetraiodothyroacetic acid (tetrac), a deaminated T4 analogue. Tetrac blocks binding of T4 and T3 to the integrin and has an array of anti-cancer and anti-angiogenic properties at v3 that are independent of its inhibition of T4- and T3-binding to the integrin.
![Page 4: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/4.jpg)
O CH2-CH-COOH
NH2
I--
I-- I--
I--3’
5’ 5
3
Thyroxine (T4)
OHO CH2-CH-COOH
NH2
I--
I--
I--3’
5’ 5
3
3,5,3’-Triiodothyronine (T3)
HO
O CH2--COOH
I--
I-- I--
I--3’
5’ 5
3
Tetrac
HO
![Page 5: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/5.jpg)
Because unmodified tetrac is a thyromimetic within cells, we re-formulated the analogue by covalently binding it via a linker to 200 nm PLGA (poly[lactic-co-glycolic acid]) nanoparticles which limit its activities to the cell surface hormone-tetrac receptor on integrin v3.
![Page 6: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/6.jpg)
H
NH
O
HN
O
NH
ONH
HN
OO
I
IOI
I
O
O OI
IOI
I
OH
NH
OO
I
I OI
I
HO PLGA nanoparticle
Nanotetrac
Four-to-eight tetrac moieties covalentlybound via a linker to a 200 nm nanoparticle
![Page 7: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/7.jpg)
At the integrin, Nanotetrac regulates via signal transducing kinases the expression of a variety of cancer-relevant and angiogen-esis-relevant genes. Nanotetrac disrupts crosstalk between v3 and adjacent vascular growth factor receptors (VEGFR, bFGFR, PDGFR, EGFR). Nanotetrac blocks radiation-induced activation of the integrin and controls plasma membrane ion transporters, e.g., NHE1, important to pHi and pHe.
![Page 8: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/8.jpg)
ACTING AT THE INTEGRIN, NANOPARTICULATE TETRAC
INDUCES A BLUEPRINT OF ANTI-CANCER GENE EXPRESSION
• DR of apoptosis inhibitors XIAP, MCL1, upregulation (UR) of pro-apoptotic CASP2, BCL2L14
• DR of catenin genes, UR of CBY1, a nuclear inhibitor of catenin activity
• Downregulation (DR) of 21 of 23 differentially-regulated proto-oncogenes and 8 of 9 cyclins
• UR of thrombospondin (THBS1), an angiogenesis inhibitor, DR of CTSL1, progenitor endothelial cell recruiter
![Page 9: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/9.jpg)
Fig. 3B
Pro-apoptosis
Cell Cycle, 2009
![Page 10: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/10.jpg)
Fig. 2A
Anti-apoptosis
Cell Cycle 2009
![Page 11: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/11.jpg)
Fig. 7
Cell Cycle, 2009
![Page 12: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/12.jpg)
Days-10 -5 0 5 10 15 20
200
400
600
800
1000
ControlTetrac 1 mg/kg (every 3rd day)Tetrac Nano 1 mg/kg (every 3rd day)
Right side
Days-10 -5 0 5 10 15 20
100
200
300
400
500
600
700
Control
Tetrac 1 mg/kg (every 3rd day)
Tetrac Nano 1 mg/kg (every 3rd day)
Left side
Mea
n T
umor
Vol
ume
(mm
3)
± S
EM
Effect of Tetrac and Tetrac Nanoparticles on Human Non-Small Cell Lung Carcinoma Xenograft
VolumeM
ean
Tum
or V
olum
e (m
m3)
± S
EM
Lung Cancer, 2012
![Page 13: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/13.jpg)
Subcutaneous treatment effect on xenograft tumor (MPanc96-luc)
after 19 daysIVIS images
Control (PBS) Tetrac (1 mg/kg) Nanotetrac (1 mg/kg)
MPanc96-luc cells injected March 7th, 2012Subcutaneous daily treatment started: March 12th, 2012IVIS: March 30th, 2012
![Page 14: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/14.jpg)
Treatment (per implant)
Tumor weight (gm.)
Control (Vehicle) 0.0423
Void NP 0.0417
Tetrac (3 µg) 0.0422
Tetrac (10 µg) 0.0125
Nanotetrac (3 µg) 0.0120
Nanotetrac (10 µg) 0.0089
Effect of Nanotetrac on human glioblastoma U87MG xenografts in nude mice
(16-day dose/implant study)
Tumor weight
0
0.01
0.02
0.03
0.04
0.05
0.06
Control(Vehicle)
Void NP (3) Tetrac (3 µg) Tetrac (10 µg) Nanotetrac (3µg)
Nanotetrac(10 µg)
Treatment groups
Tum
or w
eigh
t (gm
)
![Page 15: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/15.jpg)
Nanotetrac has been effective against xenografts of human glioma/glioblastoma, breast, prostate, pancreatic, kidney, (NSCLC and non-small cell) lung, colon and thyroid cells.
![Page 16: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/16.jpg)
• The anti-angiogenic properties of Nanotetrac involve vascular growth factor gene expression (VEGFA, bFGF), growth factor receptor gene expression (EGFR), interaction of growth factors (VEGF, bFGF, PDGF, EGF) with their specific cell surface receptors, release of vascular growth factors (bFGF), expression of the cancer cell THBS1 (TSP1) gene and endothelial cell motility. This is a broadly-based set of anti-angiogenic actions.
![Page 17: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/17.jpg)
Effect of tetrac (10 mg/kg, i.p. daily) or Nanotetrac (1.0 mg/kg, i.p. daily) on
pancreatic tumor angiogenesisH
emog
lobi
ne (
mg/
ml)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Control Tetrac Tetrac Nano
PANC-I RIGHT SIDE
Hem
oglo
bine
(m
g/m
l)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Control Tetrac Tetrac Nano
PANC-I LEFT SIDE
![Page 18: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/18.jpg)
PBS T4 (total, 0.1M)
T4+ LM609(10g)
Inhibitory effect of v3 MAB (LM609) on T4-stimulated angiogenesis in the CAM model
CAM Treatment # of branch pts ± SEM % Inhibition ± SEM
PBS 73 ± 8
T4(0.1uM) 170 ± 16 0
T4+LM609(10ug) 109 ± 9 64 ± 9
![Page 19: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/19.jpg)
Table 1 Inhibition of activities of pro-angiogenic factors in the CAM assay by Nanoterac (NT) (2 µg/CAM)
Treatment
PBS controlVoid PLGA nanoparticleT3 (6.5 ng/mL)T3 + NTT4 (100 nM)
LPS + NTBradykini (5 µg/mL)Bradykini + NTAngiotensin II (5 µg/mL)Angiotensin II + NTVEGF (2 µg/mL)VEGF + NTbFGF (1 µg/mL)bFGF + NTbFGF + VEGF + TNF-αbFGF + VEGF + TNF-α + NT
Materials and Methods CAM assay was performed in duplicate X3 by our peviously published method [23]. P values by ANOVA compared single and multiple agent-containing samples with control or samples with and without Nanotetrac (NT). All comparisons were significant at least at P < 0.01.PBS phosphate-buffered saline, PLGA poly[lactic-co-glycolic acid], LPS lipopolysaccharide, VEGF vascular endothelial growth factor, bFGF basic fibroblast growth factor, TNF-α tumor necrosis factor-α.
T4 (100 nM) + NT
![Page 20: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/20.jpg)
Fig. 5
Anti-angiogenesis
Cell Cycle, 2009
![Page 21: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/21.jpg)
THBS1
mRN
A e
xpre
ssio
n
Control Tetrac NP
Tetrac Control Tetrac NP Tetrac
VEGFA
THBS1, thrombospondin 1VEGFA, vascular endothelial growth factor A
Human medullary thyroid carcinoma cells
![Page 22: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/22.jpg)
Effect of Tetrac on Cancer Cell Implants on Angiogenesis in the CAM Model
+ Tetrac (1 µM)
Control
Increased vascular proliferation
Decreased vascular proliferation
H1299 Bronchogenic carcinoma (1 x 106 cells/CAM)
Actions of tetrac initiated nongenomically at v3culminate in a complex of genomic and nongenomiceffects on proliferation.
![Page 23: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/23.jpg)
• Integrin v3 contains a cell surface receptor for T4, T3.
• Tetrac and nanoparticulate tetrac inhibit agonist hormone action at the receptor and are probes for contributions of the receptor.
• In vitro, T4, T3 act at the integrin receptor via ERK1/2 to support tumor cell proliferation (breast, glioma, head-and-neck, thyroid, ovary, pancreas, kidney, lung, prostate) and angiogenesis; tetrac and Nanotetrac block these actions.
Summary
![Page 24: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/24.jpg)
Summary 2
• Acting via the cell surface receptor on v3, Nanotetrac coherently modulates expression of multiple genes relevant to tumor cell survival.
• Receptor-initiated actions of thyroid hormone analogues also include modulation of crosstalk between the integrin and nearby vascular growth factor receptors and crosstalk with nuclear hormone receptor proteins, such as ER.
![Page 25: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/25.jpg)
Summary 3
• Nanotetrac also blocks tumor cell repair of radiation-induced double-strand DNA breaks
• Nanotetrac prolongs intracellular residence time of doxorubicin, etoposide and cisplatin, apparently via NHE1 and consequent alterations in pHi and pHe that affect P-glycoprotein and organic cation transporter function.
![Page 26: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/26.jpg)
COLLABORATORS
Shaker A. Mousa, PhD Albany
Hung-Yun Lin, PhD Albany
Heng-Yuan Tang, MA Albany
Thangirala Sudha, PhD Albany
Faith B. Davis, MD Albany
Murat Yalcin, DVM, PhD Turkey
Sandra Incerpi, PhD Italy
Osnat Ashur-Fabian, PhD Israel
![Page 27: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/27.jpg)
![Page 28: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/28.jpg)
Hypothyroid
Median Survival: 10.1 mos
Non-hypothyroid
Median Survival: 3.1 mos
Hercbergs AA et al, Anticancer Res, 2003
![Page 29: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/29.jpg)
PBS
A
T4 T4 + Tetrac
B
Summary of effects of T4, T4-agarose and tetrac on angiogenesis Treatment Angiogenesis Index PBS 67 9 T4 (0.1 nM) 156 16** Tetrac (0.1 M) 76 9 T4 + tetrac 66 6 T4-agarose (total, 0.1 M) 194 28** T4-agarose + tetrac 74 7
C PBS T4-ag T4-ag + Tetrac
Angiogenesis in the CAM
![Page 30: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/30.jpg)
0
2
4
6
8
10
0 1 30
1
2
3
4
5
Nor
mal
ized
Gen
e Ex
pres
sion Angiopoietin-1 Angiopoietin-2
Nor
mal
ized
Gen
e Ex
pres
sion
0 1 3Tetrac (µM)VEGF
(50 ng/ml)
Tetrac (µM)VEGF
(50 ng/ml)
A B
Ang-2 primes vascular endothelium for action of vascular growth factors
HDMEC cells
![Page 31: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/31.jpg)
Fig. 9
Tota
l Ce
ll C
ou
nts
2
3
4
5
6
7
x 10
0000
Effect of Tetrac and Nano Tetrac on Cell Proliferation in CV-1 cells
0
5
10
15
20
Mill
ions
Tota
l Ce
ll C
ou
nts
Effect of Tetrac and Nano Tetrac on Cell Proliferation in 293T cells
A.
B.
CV-1, monkey kidney fibroblast293T, human kidney epithelial cell
![Page 32: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/32.jpg)
Treatment Tumor weight (gm)
PBS (Control) 0.123 *Nanotetrac (1mg/kg) 0.066
Nanotetrac (1mg/kg) (microfluidizer) 0.073
*
![Page 33: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/33.jpg)
Control (PBS) Tetrac (0.1 mg/kg)
Nanotetrac (0.1 mg/kg)
MPanc96-luc cells injected March 7th, 2012Intra tumor treatment (once a week) started: March 12 th, 2012IVIS: March 30th, 2012
![Page 34: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/34.jpg)
Time (day)
-15 -10 -5 0 5 10 15
Tum
or v
olum
e m
m3
100
150
200
250
300
350ControlTetracTetrac Nano
PANC-1 Left Side
Time (day)
-15 -10 -5 0 5 10 15
Tum
or v
olum
e m
m3
50
100
150
200
250
300
350
400
450ControlTetracTetrac Nano
PANC-1 Right Side
Effect of tetrac (10 mg/kg, i.p. daily) or tetrac PLGA nano (1.0 mg/kg, i.p. daily) on
human pancreatic cancer xenografts
![Page 35: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/35.jpg)
Integrins are 24 heterodimeric structural proteins of the plasma membrane that are critical to cell-cell and cell-ECM matrix protein interactions. Integrin v3 binds protein molecules—vitronectin, fibronectin, osteopontin—and recently has been appreciated to bind small molecules. The latter include thyroid hormone and its analogues, resveratrol and dihydrotestosterone.
![Page 36: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/36.jpg)
0
1
2
3
4
5pERK1/2PCNApTyr-p85-PI 3-Kp85-PI 3-K
0
1
2
3
4
5
6
pERK1/2PCNA
U87MG (GBM) cells
Blot: anti-pERK1/2Nucleus
Blot: anti-PCNA
Blot: anti-pTyrp85-PI 3-KCytosol
T4 (M) _10-9 10-8 10-7 10-6
- pERK1- pERK2
- PCNA
- pTyr-p85
48 kDa -
37 kDa -
37 kDa -
84 kDa -
T3 (10-7 M)
Rel
ativ
e I
.O.D
.
-PI 3-K
T3 (M) _ 10-9 10-8 10-7 10-6
Blot: anti-pTyrp85-PI 3-KCytosol
10-10
Blot: anti-p85-PI 3-K
- p85-PI 3-K
Blot: anti-pERK1/2Nucleus
Blot: anti-PCNA
- pERK1- pERK2
- PCNA
84 kDa -
84 kDa -
48 kDa -
37 kDa -
37 kDa -
Rel
ativ
e
I.O.D
.
- pTyr-p85-PI 3-K
T3 T4
Fig. 1
In vitro stimulation of cell proliferation(PCNA), activation of ERKs, PI3K bythyroid hormone analogues
![Page 37: NANOTETRAC TARGETS THE THYROID HORMONE RECEPTOR ON INTEGRIN v 3 TO PROMOTE APOPTOSIS, DISRUPT CELL DEFENSE PATHWAYS AND BLOCK ANGIOGENESIS Paul J](https://reader036.vdocument.in/reader036/viewer/2022062518/56649d825503460f94a67f0f/html5/thumbnails/37.jpg)
Index of double-stranded DNA breaks
Tetrac-induced Radiosensitization